Boundless Bio (BOLD) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Boundless Bio (BOLD) has outperformed Rani Therapeutics (RANI) over the past year, gaining 105.3% versus a loss of 68.6%. Rani Therapeutics is the larger company by market cap ($59.0 million vs $54.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | RANI |
|---|---|---|
| Share price | $2.32 | $0.5111 |
| Market cap | $54.78M | $59.03M |
| 1-day change | -2.52% | -11.97% |
| YTD return | +93.33% | -62.14% |
| 1-year return | +105.31% | -68.64% |
| 5-year return | — | -98.34% |
| EPS (TTM) | $-2.46 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.63M |
| Revenue growth (YoY) | — | +58.85% |
| Net income (latest FY) | $-58.20M | $-29.67M |
| Operating margin | — | -2345.99% |
| Net margin | — | -1817.09% |
| 52-week high | $3.16 | $1.69 |
| 52-week low | $0.961 | $0.502 |
| Distance from 52-week high | -26.68% | -69.76% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +72.41% | +1308.73% |
| Average volume | 131.34K | 545.67K |
| Shares outstanding | 23.61M | 115.49M |
| Employees | 28 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed RANI by 174.0 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
BOLD vs RANI FAQ
Which is bigger, Boundless Bio or Rani Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $54.78M for Boundless Bio (BOLD).
Which stock has performed better over the past year, BOLD or RANI?
BOLD returned +105.31% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.